Higher discontinuation and lower survival rates are likely in elderly Japanese patients with advanced hepatocellular carcinoma receiving sorafenib

Tolerance and outcome of patients with unresectable hepatocellular carcinoma treated with sorafenib

(2010) Violaine Ozenne et al.   EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY

Current status of molecularly targeted therapy for hepatocellular carcinoma: clinical practice

(2010) Masatoshi Kudo   International Journal of Clinical Oncology

Complete remission of unresectable hepatocellular carcinoma treated with reduced dose of sorafenib: a case report

(2010) Sean Xiang Wang et al.   Targeted Oncology

Statins Are Associated With a Reduced Risk of Hepatocellular Carcinoma in a Large Cohort of Patients With Diabetes

(2009) Hashem B. El–Serag et al.   GASTROENTEROLOGY

Sorafenib for Treatment of Renal Cell Carcinoma: Final Efficacy and Safety Results of the Phase III Treatment Approaches in Renal Cancer Global Evaluation Trial

(2009) Bernard Escudier et al.   JOURNAL OF CLINICAL ONCOLOGY

Predictive factors for severe toxicity of sunitinib in unselected patients with advanced renal cell cancer

(2008) A A M van der Veldt et al.   BRITISH JOURNAL OF CANCER

Phase 2 open-label study of single-agent sorafenib in treating advanced hepatocellular carcinoma in a hepatitis B-endemic Asian population

(2008) Thomas Yau et al.   CANCER

Design and Endpoints of Clinical Trials in Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   JNCI-Journal of the National Cancer Institute

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

(2008) Ann-Lii Cheng et al.   LANCET ONCOLOGY

Sorafenib in Advanced Hepatocellular Carcinoma

(2008) Josep M. Llovet et al.   NEW ENGLAND JOURNAL OF MEDICINE

Outcomes for Elderly, Advanced-Stage Non–Small-Cell Lung Cancer Patients Treated With Bevacizumab in Combination With Carboplatin and Paclitaxel: Analysis of Eastern Cooperative Oncology Group Trial 4599

(2007) Suresh S. Ramalingam et al.   JOURNAL OF CLINICAL ONCOLOGY